Among significant news in a holiday spattered week, Dutch biotech argenx gained another approval in Japan for its Vyvdura (efgartigimod alfa and hyaluronidase-qvf), this time for adult patients with ...

Regeneron acquires UK-based Oxular, adding ocular delivery technology and Phase II therapy OXU-001 for diabetic macular edema ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

One of the most promising areas of medical innovation in the next five years is immuno-oncology (I-O)/cancer therapeutics ...

Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that ...

WuXi Biologics has signed a deal with Sino Biopharm to develop a first-in-class monoclonal antibody targeting an undisclosed ...

Kazia Therapeutics faces a setback as the FDA deems accelerated approval for brain cancer drug paxalisib unlikely despite ...

US biotech Capricor Therapeutics today announced the completion of the submission of its Biologics License Application (BLA) ...

California-based IDEAYA Biosciences has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo ...

Hutchmed sells its 45% stake in SHPL for $608 million, aligning with its focus on oncology and immunology. Proceeds will fund ...

The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) ...

It has been a year since the launch of Zepbound (tirzepatide) for obesity, and US pharma major Eli Lilly’s competition with ...